Astel­las forges a $390M deal to buy a biotech fo­cused on Ronald Evans’ ‘ex­er­cise-in-a-pill’ tech

For years now, Salk’s Ron Evans — a cel­e­brat­ed se­r­i­al en­tre­pre­neur in sci­en­tif­ic cir­cles — has been con­cen­trat­ing on the po­ten­tial of a new path­way for turn­ing your av­er­age couch pota­to ro­dent in­to Mighty Mouse — with­out ex­er­cise. And now Astel­las has stepped in to buy the Cam­bridge, MA-based biotech that was one of the ear­ly en­thu­si­asts for this tech­nol­o­gy and its po­ten­tial ap­pli­ca­tion in Duchenne mus­cu­lar dy­s­tro­phy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER